UNSPSC 51182711: Glimepiride/metformin

Glimepiride/metformin is a fixed-dose combination therapy of an agent of the biguanide class and a sulfonylurea used to treat high blood sugar levels caused by type 2 diabetes.

UNSPSC 51182711 Glimepiride/metformin is a Commodity code tracking pharmaceutical procurement, but the recent state and local opportunities posted under this code show minimal alignment with the code's nominal scope. Of the fourteen opportunities listed, only two involve pharmaceutical services delivery at scale—a long-term care facility pharmacy contract (Dane County) and an emergency medical services pharmaceutical and supply procurement (City of Tucson)—while the remainder span unrelated categories including aquatic facility operations, drug deactivation systems procurement, forensic drug standards, naloxone distribution, opioid settlement grants, and county networking events. The code does not surface active market demand for glimepiride/metformin specifically, nor do the recent solicitations reflect routine state and local ordering of this branded diabetes combination medication.

The two opportunities most closely aligned with pharmaceutical procurement are the Dane County RFP for pharmacy services at Badger Prairie Health Care Center (response due October 22, 2026) and the City of Tucson Fire Department's RFP for BLS/ALS pharmaceuticals and supplies with VendNovation vending machines (response due June 24, 2026, federally funded through ARPA, HUD, and FTA). Both solicitations specify comprehensive distribution, inventory management, and fulfillment obligations rather than commodity purchasing of individual medications. Issuers span county health departments, city fire departments, mental health providers, and forensic laboratories across Florida, Wisconsin, Arizona, Texas, and Oregon. Geographic activity in the recent block concentrates in Florida (Collier County, Clay County, Seminole County, Marion County, Pinellas County) with secondary activity in the Upper Midwest and Southwest. The code shows limited direct relevance for vendors focused on glimepiride/metformin distribution or supply.